We are live on
!
Find out more
CP
Catalys Pacific Portfolio holdings
AUM
$229M
1-Year Est. Return
100.3%
This Fund
S&P 500
This Quarter
Est. Return
-4.02%
1 Year Est. Return
+100.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$107M
AUM Growth
–
Cap. Flow
+$95.8M
Cap. Flow
% of AUM
89.81%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
3
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mineralys Therapeutics
MLYS
|
+$72.2M |
| 2 |
HLVX
HilleVax
HLVX
|
+$17.4M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
+$6.22M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
CCM
CIS
CCP
AIA
TCA
NIA
SCM
AF
Catalys Pacific's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Catalys Pacific, which disclosed 3 positions worth $107M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Mineralys Therapeutics: 9,194,579 shares worth $79.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Catalys Pacific's largest Q4 2023 buy was Mineralys Therapeutics: 9,194,579 shares worth $79.1M.
- Catalys Pacific's ten largest holdings make up 100% of its $107M portfolio in Q4 2023.
- Catalys Pacific disclosed 3 positions in Q4 2023, its first 13F filing on record.
Based on Catalys Pacific's 13F filing for Q4 2023, filed 14 Feb 2024.